MADRIGAL PHARMACEUTICALS, INC.
MDGL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MDGL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MDGL
Madrigal Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for metabolic dysfunction-associated steatohepatitis (MASH), with its approved product Rezdiffra (resmetirom) and a pipeline of early-stage candidates.
Key risk: Commercialization dependence
BioSniper Score
Based on 6 of 6 signals
Market Cap
$12.33B
Cash Runway
—
Lead Asset
ervogastat (Phase 2)
Next Catalyst
Phase3_Topline · Jan 1, 2027Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 10 clinical trials · 3 catalysts for MADRIGAL PHARMACEUTICALS, INC..
Madrigal Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for metabolic dysfunction-associated steatohepatitis (MASH), with its approved product Rezdiffra (resmetirom) and a pipeline of early-stage candidates.
- Received accelerated FDA approval for Rezdiffra (resmetirom) in March 2024 and EC approval in August 2025 [sec_mda · as of 2026-07-30].
- Cash and equivalents of $292.9M as of 2026-06-30, with total revenue of $364.3M and a net loss of $57.9M for the same period [sec].
- Accumulated deficit of $2,090.5M as of December 31, 2025 [sec_mda · as of 2026-02-19].
- Pipeline includes MGL-2086 (oral GLP-1 receptor agonist), ervogastat (DGAT2 inhibitor), six siRNA programs, and additional preclinical MASH candidates [sec_mda · as of 2026-02-19].
- Entered into a senior secured credit facility in July 2025 providing up to $500.0 million [sec_mda · as of 2026-07-30].
What works
- Rezdiffra is the first FDA-approved therapy for MASH, addressing a large unmet medical need with no prior approved treatments [sec_mda · as of 2026-07-30].
- The company has built a broad pipeline of complementary mechanisms (GLP-1, DGAT2, siRNA) to strengthen its position in MASH care [sec_mda · as of 2026-02-19].
- Cash resources are sufficient to fund operations past one year from the latest financial statements, providing near-term operational stability [sec_mda · as of 2026-05-06].
What to weigh
- The company has incurred significant net losses since inception, with an accumulated deficit of $2,090.5M as of December 31, 2025 [sec_mda · as of 2026-02-19].
- Future liquidity requirements are substantial and depend on successful commercialization of Rezdiffra, geographic expansion, and clinical trial outcomes [sec_mda · as of 2026-05-06].
- The probability of success for pipeline candidates is uncertain, and development costs are difficult to predict [sec_mda · as of 2026-05-06].
From the filings
Quoted directly from source documents.
Rezdiffra received accelerated FDA approval in March 2024 and EC approval in August 2025.
“We received FDA approval for Rezdiffra in March 2024 and EC approval for Rezdiffra in August 2025.”
SEC MD&A · July 30, 2026
Accumulated deficit as of December 31, 2025 was $2,090.5 million.
“accumulated deficit of $2,090.5 million as of December 31, 2025”
SEC MD&A · February 19, 2026
Pipeline includes MGL-2086, ervogastat, six siRNA programs, and additional preclinical MASH candidates.
“acquired rights to MGL-2086, an oral GLP-1 receptor agonist, ervogastat, an oral DGAT2 inhibitor, six siRNA programs and additional preclinical MASH candidates”
SEC MD&A · February 19, 2026
Cash resources are sufficient to fund operations past one year from the issuance of the financial statements.
“we believe our available cash resources are sufficient to fund our operations past one year from the issuance of the financial statements contained herein”
SEC MD&A · May 6, 2026
Catalyst timeline
- 2027-01-01 · Phase 3 Topline: A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on L — Topline results from a Phase 3 study evaluating resmetirom's effect on liver-related outcomes.
- 2027-04-01 · Phase 3 Topline: A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and — Topline results from an open-label extension study assessing long-term safety and efficacy of resmetirom.
- 2028-01-01 · Phase 3 Topline: A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (Resmetirom — Topline results from a multinational Phase 3 study of resmetirom in MASH.
Risks & what to watch (4)›
Key risks
- Commercialization dependence — Future liquidity depends on successful commercialization of Rezdiffra and geographic expansion [sec_mda · as of 2026-05-06].
- Clinical trial uncertainty — Pipeline candidates face high development risk and unpredictable costs [sec_mda · as of 2026-05-06].
- Accumulated losses — Accumulated deficit of $2,090.5M as of December 31, 2025 indicates ongoing financial strain [sec_mda · as of 2026-02-19].
- Liquidity covenant compliance — Must maintain compliance with liquidity covenant in Financing Agreement [sec_mda · as of 2026-02-19].
What to watch
- Rezdiffra commercial launch trajectory and revenue growth [sec_mda · as of 2026-07-30].
- Phase 3 topline data readouts for resmetirom in 2027 [catalyst_timeline].
- Progress of pipeline candidates (MGL-2086, ervogastat, siRNA programs) [sec_mda · as of 2026-02-19].
- Cash burn rate and ability to manage debt under the $500M credit facility [sec_mda · as of 2026-07-30].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run MADRIGAL PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MADRIGAL PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 1.38 · 0% dilution
Lead: Approved
3 candidates
3 upcoming, next in ~124d
0 buys · 41 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
380
Total value held
$12.51B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 4,037,294 | $2.10B |
| baker bros. advisors lp | 2,141,701 | $1.12B |
| rtw investments, lp | 1,993,687 | $1.04B |
| vanguard capital management llc | 1,654,288 | $866.0M |
| blackrock, inc. | 1,559,965 | $816.6M |
| vanguard portfolio management llc | 841,145 | $440.3M |
| wellington management group llp | 694,958 | $363.8M |
| state street corp | 609,525 | $319.1M |
| citadel advisors llc | 602,543 | $315.4M |
| fmr llc | 511,728 | $267.9M |
Showing top 10 of 380 institutional holders of MADRIGAL PHARMACEUTICALS, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 19.7%
- Days to cover
- 13.3
- Shares short
- 3,854,441
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MDGL short interestGovernance
Frequently asked questions
What is the AI investment thesis for MADRIGAL PHARMACEUTICALS, INC.?
Madrigal Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for metabolic dysfunction-associated steatohepatitis (MASH), with its approved product Rezdiffra (resmetirom) and a pipeline of early-stage candidates.
What is MADRIGAL PHARMACEUTICALS, INC.'s lead drug candidate?
MADRIGAL PHARMACEUTICALS, INC.'s most advanced tracked candidate is ervogastat (Phase 2) for Metabolic dysfunction-associated steatohepatitis (MASH).
What is MADRIGAL PHARMACEUTICALS, INC.'s next catalyst?
MADRIGAL PHARMACEUTICALS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on L" — expected January 1, 2027.
Who is the CEO of MADRIGAL PHARMACEUTICALS, INC.?
Mr. William J. Sibold is the chief executive officer of MADRIGAL PHARMACEUTICALS, INC. (MDGL).
Where is MADRIGAL PHARMACEUTICALS, INC. headquartered?
MADRIGAL PHARMACEUTICALS, INC. (MDGL) is headquartered in West Conshohocken, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.